Form 8-K NxStage Medical, Inc. For: Feb 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Selloff in NxStage Medical (NXTM) Seems 'Excessive'; BTIG Reaffirms at 'Buy'
February 11, 2016 9:48 AM ESTBTIG is out in defense of NxStage Medical, Inc. (NXTM) following the company's Q4, FY16 results reported on Wednesday. The firm rates NxStage at Buy with a price target of $27.
Analyst Sean Lavin noted that NxStage posted FY16 revenue of $336 million, which exceeded the company's outlook of $332 - $333 million. But, a... More
